Trovafloxacin susceptibility of aerobic clinical bacterial isolates from Sweden

Scandinavian Journal of Infectious Diseases

Volumn 31, Issue 6, 1999, Pages 567-572

  Rylander, Margareta ^a,g   Walder, Mats ^b   Lind Brandberg, Lena ^c   Larsson, Peter ^d   Törnqvist, Eva ^e   Monsen, Tor ^f   Kronvall, Göran ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^f UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; TROVAFLOXACIN;

ACINETOBACTER; AEROBIC BACTERIUM; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL PNEUMONIA; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DIFFUSION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEUS MIRABILIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS SAPROPHYTICUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS GROUP A; STREPTOCOCCUS GROUP C; STREPTOCOCCUS GROUP G; SWEDEN;

EID: 0033370337     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365549950164454     Document Type: Article

References (23)

1. Brighty KE, Gootz TD. The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother 1997; 39: 1-14.
2. Gooding BB, Jones RN. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Ag Chemother 1993; 37: 349-53.
3. Eliopoulos GM, Klimm K, Eliopoulos CT, Ferraro MJ, Moellering Jr RC. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of Gram-positive bacteria. Antimicrob Ag Chemother 1993; 37: 366-70.
4. Child J, Andrews J, Boswell F, Brenwald N, Wise R. The in-vitro activity of CP-99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. J Antimicrob Chemother 1995; 35: 869-76.
5. Verbist L, Verhaegen J. In vitro activity of trovafloxacin versus ciprofloxacin against clinical isolates. Eur J Clin Microbiol Infect Dis 1996; 15: 683-5.
6. Martinez-Martinez L, Joyanes P, Pascual A. Terrero E, Perea EJ. Activity of eight fluoroquinolones against enterococci. Clin Microbiol Infect 1997; 3: 497-9.
7. Pankuch GA, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. J Antimicrob Chemother 1995; 35: 230-2.
8. Klugman K, Wasas A. In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and -resistant Streptococcus pneumoniae. J Antimicrob Chemother 1995; 36: 873-4.
9. Knapp JS, Neal SW, Parekh MC, Rice RJ. In vitro activity of a new fluoroquinolone, CP-99,219, against strains of Neisseria gonorrhoeae. Antimicrob Ag Chemother 1995; 39: 987-9.
10. Bonilla HF, Zarins LT, Bradley SF, Kauffman CA. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin. Diagnostic Microbiol Infect Dis 1996; 26: 17-21.
11. Dembry LM, Farrel PA, Orcutt DR, Gerrity LA, Andriole VT. In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest. J Antimicrob Chemother 1997; 39: 35-42.
12. Citron DM, Appleman MD. Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections. Antimicrob Ag Chemother 1997; 41: 2312-6.
13. Olsson-Liljequist B, Hoffman BM, Hedlund J. Activity of trovafloxacin against blood isolates of Streptococcus pneumoniae in Sweden. Eur J Clin Microbiol Infect Dis 1996; 15: 671-5.
14. NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 4th edn, Approved Standard. M7-A4. NCCLS, Wayne, PA, USA 1997; 17: 1-29.
15. Björklind A, Ringertz S, Kronvall G. Types of interpretive errors in susceptibility testing. APMIS 1989; 97: 941-8.
16. Olsson-Liljequist B, Larsson P, Walder M, Miörner H. Antimicrobial susceptibility testing in Sweden. III. Methodology for susceptibility testing. Scand J Infect Dis 1997; Suppl 105: 13-23.
17. Ringertz S, Olsson-Liljequist B, Kahlmeter G, Kronvall G. Antimicrobial susceptibility testing in Sweden. II. Species-related zone diameter breakpoints to avoid interpretive errors and guard against unrecognized evolution of resistance. Scand J Infect Dis 1997; Suppl 105: 8-12.
18. Kronvall G. Response to Drs Ian Phillips and Anna King. Clin Microbiol Infection 1998; 4: 232.
19. Kronvall G, Rylander M, Walder M, Lind-Brandberg L, Larsson P, Törnqvist E, et al. Calibration of disk diffusion antibiotic susceptibility testing. Calculation of species-related trovafloxacin interpretive zone breakpoints for the individual laboratory and aspects on the selection of disk potency. Scand J Infect Dis 1999; 31: 573-8.
20. Edelstein PH. Antimicrobial chemotherapy for Legionnaires disease: time for a change. Ann Intern Med 1998; 129: 328-30.
21. Fuchs PC, Barry AL, Brown SD. Tentative interpretive criteria for testing the susceptibility of Streptococcus pneumoniae to eight fluoroquinolones. Diagnostic Microbiol Infect Dis 1996; 26: 23-7.
22. Evans ME, Titlow WB. Selection of fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus with ciprofloxacin and trovafloxacin. Antimicrobial Ag Chemother 1998; 42: 727.
23. M'Zali FH, Nice C, Dalhoff A, et al. Differential selection of quinolone resistance by new quinolones in methicillin-sensitive (MSSA) and -resistant (MRSA) Staphylococcus aureus. Abstract P130. Clin Microbiol Infection 1999; 5: Suppl 3: 119-20.